Literature DB >> 35134470

Meta-analysis of microRNA profiling data does not reveal a consensus signature for B cell acute lymphoblastic leukemia.

Modeline N Longjohn1, Willow R B Squires1, Sherri L Christian2.   

Abstract

B cell acute lymphoblastic leukemia (B-ALL) is the most prevalent pediatric cancer. MicroRNAs (miRNAs) are 18-22nt non-coding transcripts shown to be essential for the development of many cancers. While some miRNAs are reportedly expressed differentially between healthy and B-ALL, no studies have reported a consensus miRNA signature. Therefore, we performed a reanalysis of five miRNA datasets to identify differentially expressed miRNAs (DEmiRs) and a meta-analysis of previously identified DEmiRs from 25 studies. Overall, the re-analysis showed that the DEmiR data clustered by platform and not by disease state. The meta-analysis also did not reveal a consensus miRNA signature as there were many miRNAs upregulated in some studies and downregulated in others. However, eight promising miRNAs (miR-181b, miR-128b, miR-181a, miR-128, miR-128a, miR-181c, miR-155, miR-142-3p, and miR-451) were identified from the meta-analysis, which could be the basis of future investigations. These analyses reveal that standardization of miRNA isolation and analysis is needed in B-ALL to enable cross-study comparisons and identify a consensus signature.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  B cell acute lymphoblastic leukemia; Gene expression signature; Meta-analysis; microRNA

Mesh:

Substances:

Year:  2022        PMID: 35134470     DOI: 10.1016/j.gene.2022.146211

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  1 in total

Review 1.  MicroRNAs and the Diagnosis of Childhood Acute Lymphoblastic Leukemia: Systematic Review, Meta-Analysis and Re-Analysis with Novel Small RNA-Seq Tools.

Authors:  Ioannis Kyriakidis; Konstantinos Kyriakidis; Aspasia Tsezou
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.